Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:7870044rdf:typepubmed:Citationlld:pubmed
pubmed-article:7870044lifeskim:mentionsumls-concept:C0332307lld:lifeskim
pubmed-article:7870044lifeskim:mentionsumls-concept:C1882598lld:lifeskim
pubmed-article:7870044lifeskim:mentionsumls-concept:C1523873lld:lifeskim
pubmed-article:7870044lifeskim:mentionsumls-concept:C0016904lld:lifeskim
pubmed-article:7870044lifeskim:mentionsumls-concept:C0033004lld:lifeskim
pubmed-article:7870044lifeskim:mentionsumls-concept:C0441472lld:lifeskim
pubmed-article:7870044pubmed:issue2lld:pubmed
pubmed-article:7870044pubmed:dateCreated1995-3-29lld:pubmed
pubmed-article:7870044pubmed:abstractTextCertain endogenous pregnanediols (5 alpha-pregnan-3 alpha,20 alpha-diol and 5 beta-pregnan-3 alpha,20 beta-diol) were observed to have limited efficacy as allosteric modulators of t-[35S]butylbicyclophosphorothionate ([35S]TBPS) and [3H]flunitrazepam binding to sites on the gamma-aminobutyric acid (GABA)A receptor complex in rat brain. In contrast, 3 alpha-hydroxy-5 alpha-pregnan-20-one (3 alpha,5 alpha-P) and 3 alpha-hydroxy-5 beta-pregnan-20-one (3 alpha,5 beta-P) have full efficacy. Moreover, 3 alpha,5 beta-P but not 3 alpha,5 alpha-P recognizes high (nanomolar) and low (micromolar) affinity neuroactive steroid sites in these allosteric modulatory assays. The concentration-response curve for 3 alpha,5 alpha-P modulation of [35S]TBPS binding was shifted rightward in the presence of these pregnanediols and GABA. The maximum shift produced by these pregnanediols never exceeded the concentration-response curve obtained with 3 alpha,5 alpha-P alone in the absence of GABA. Additionally, neither 5 alpha-pregnan-3 alpha,20 alpha-diol nor 5 beta-pregnan-3 alpha,20 beta-diol had any effect on the site recognized by 3 alpha,5 alpha-P in the absence of GABA. The difference in the affinities of the two apparent sites (29 nM versus 152 nM in the presence and absence of GABA, respectively) recognized by 3 alpha,5 alpha-P is only approximately 5-fold. In contrast, the difference between the high (30 nM) and low (7 microM) affinity sites discriminated by 3 alpha,5 beta-P is > 200-fold. Thus, the selective interaction between the high affinity site recognized by 3 alpha,5 beta-P and these pregnanediols can be clearly observed. A saturating concentration of 5 beta-pregnan-3 alpha,20 beta-diol selectively eliminated the high affinity component recognized by 3 alpha,5 beta-P, whereas 5 alpha-pregnan-3 alpha,20 alpha-diol did not completely abolish the high affinity site. 5 alpha-Pregnan-3 alpha,20 alpha-diol recognized only a portion of the high affinity sites discriminated by 3 alpha,5 beta-P, relative to 5 beta-pregnan-3 alpha,20 beta-diol, whereas the two pregnanediols recognized a similar population of sites mediating 3 alpha,5 alpha-P inhibition of [35S]TBPS binding. Collectively, these studies provide evidence that the limited efficacy of certain pregnanediols as allosteric modulators of [35S]TBPS binding may be explained in part by selectivity for the high affinity site recognized by 3 alpha,5 beta-P.(ABSTRACT TRUNCATED AT 400 WORDS)lld:pubmed
pubmed-article:7870044pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7870044pubmed:languageenglld:pubmed
pubmed-article:7870044pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7870044pubmed:citationSubsetIMlld:pubmed
pubmed-article:7870044pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7870044pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7870044pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7870044pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7870044pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7870044pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7870044pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7870044pubmed:statusMEDLINElld:pubmed
pubmed-article:7870044pubmed:monthFeblld:pubmed
pubmed-article:7870044pubmed:issn0026-895Xlld:pubmed
pubmed-article:7870044pubmed:authorpubmed-author:ChenJ SJSlld:pubmed
pubmed-article:7870044pubmed:authorpubmed-author:HokK AKAlld:pubmed
pubmed-article:7870044pubmed:authorpubmed-author:UkSSlld:pubmed
pubmed-article:7870044pubmed:authorpubmed-author:HawkinsonJ...lld:pubmed
pubmed-article:7870044pubmed:authorpubmed-author:LiuVVlld:pubmed
pubmed-article:7870044pubmed:authorpubmed-author:McCauleyL DLDlld:pubmed
pubmed-article:7870044pubmed:issnTypePrintlld:pubmed
pubmed-article:7870044pubmed:volume47lld:pubmed
pubmed-article:7870044pubmed:ownerNLMlld:pubmed
pubmed-article:7870044pubmed:authorsCompleteYlld:pubmed
pubmed-article:7870044pubmed:pagination354-62lld:pubmed
pubmed-article:7870044pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:7870044pubmed:meshHeadingpubmed-meshheading:7870044-...lld:pubmed
pubmed-article:7870044pubmed:meshHeadingpubmed-meshheading:7870044-...lld:pubmed
pubmed-article:7870044pubmed:meshHeadingpubmed-meshheading:7870044-...lld:pubmed
pubmed-article:7870044pubmed:meshHeadingpubmed-meshheading:7870044-...lld:pubmed
pubmed-article:7870044pubmed:meshHeadingpubmed-meshheading:7870044-...lld:pubmed
pubmed-article:7870044pubmed:meshHeadingpubmed-meshheading:7870044-...lld:pubmed
pubmed-article:7870044pubmed:meshHeadingpubmed-meshheading:7870044-...lld:pubmed
pubmed-article:7870044pubmed:meshHeadingpubmed-meshheading:7870044-...lld:pubmed
pubmed-article:7870044pubmed:meshHeadingpubmed-meshheading:7870044-...lld:pubmed
pubmed-article:7870044pubmed:meshHeadingpubmed-meshheading:7870044-...lld:pubmed
pubmed-article:7870044pubmed:meshHeadingpubmed-meshheading:7870044-...lld:pubmed
pubmed-article:7870044pubmed:meshHeadingpubmed-meshheading:7870044-...lld:pubmed
pubmed-article:7870044pubmed:meshHeadingpubmed-meshheading:7870044-...lld:pubmed
pubmed-article:7870044pubmed:meshHeadingpubmed-meshheading:7870044-...lld:pubmed
pubmed-article:7870044pubmed:year1995lld:pubmed
pubmed-article:7870044pubmed:articleTitleSelective actions of certain neuroactive pregnanediols at the gamma-aminobutyric acid type A receptor complex in rat brain.lld:pubmed
pubmed-article:7870044pubmed:affiliationDepartment of Pharmacology, College of Medicine, University of California, Irvine 92717.lld:pubmed
pubmed-article:7870044pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:7870044pubmed:publicationTypeIn Vitrolld:pubmed
pubmed-article:7870044pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:7870044pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed